Efficacy Of Loralatinib After Combination With Alectinib Central Lung Disease In One Patient In Kinase-Positive Anaplastic Lymphoma Small Cell Lung Cancer: A Case Report

Abstract

Background: Tyrosine kinase inhibitors are the standard drug treatment for anaplastic lymphoma anaplastic lymphoma kinase-positive non-small cell lung cancer, and treatment with these agents is indicated. contributing to the long-term survival of patients. However, there is no consensus after the treatment method Early onset of drug-induced interstitial lung disease by tyrosine kinase kinase inhibitors in anaplastic lymphoma. Here, we present a case of successful treatment with lolatinib after the onset of drug-induced lung disease. induced by alectinib. Case presentation: A 57-year-old Japanese man was diagnosed with stage IVB non-small cell lung cancer. bronchoscopy, but gene mutation testing was not possible due to the small number of samples. next At diagnosis, first-line cisplatin/pemetrexed therapy was initiated, but the patient developed renal dysfunction.